Earnings, Guidance And ESOP Filing Put Alphatec Holdings In Focus

Alphatec Holdings (ATEC) is back on investors’ radar after second quarter 2026 results showed a narrower net loss, full year revenue guidance was reaffirmed, and an ESOP related shelf registration was filed.

The earnings update, the reaffirmed 2026 revenue outlook and the ESOP related shelf registration have arrived after a difficult stretch for Alphatec Holdings, with the share price at US$9.31 and a year to date share price return that has fallen 55.15%. At the same time, the 90 day share price return of 23.8% contrasts with a 1 year total shareholder return that has declined 37.81%, which suggests recent momentum has picked up even as longer term investors are still carrying losses.

If this kind of rebound has you thinking about where else capital might rotate within healthcare, it could be worth scanning for other medical technology and related leaders through the 43 healthcare AI stocks

After Alphatec Holdings’ sharp year to date fall and more recent rebound, the question now is whether most of the easy upside has already been taken or if current pricing still leaves meaningful room ahead.

Most Popular Narrative: 41.8% Undervalued

At a last close of $9.31 versus a narrative fair value of $16.00, Alphatec Holdings is framed as materially undervalued, with that gap linked directly to long term earnings and cash flow expectations under a single structured view of the future.

Operational discipline, expense control, and infrastructure scalability have inflected the company into sustained profitability and free cash flow generation, directly improving net income and strengthening the balance sheet for future growth investment.

Want to see what powers that confidence in Alphatec Holdings? The narrative leans on rapid earnings gains, rising margins and a richer future profit multiple. Curious which specific growth and profitability assumptions sit underneath that $16.00 fair value?

Result: Fair Value of $16.00 (UNDERVALUED)

However, Alphatec Holdings still faces pressure from ongoing operating losses and intense competition in spine care, which could limit the bullish narrative if revenue momentum slows.

Another View On Alphatec Holdings’ Valuation

The narrative fair value points to clear upside for Alphatec Holdings, yet the current P/S ratio tells a more cautious story. A P/S of 1.8x sits slightly above peers at 1.7x, although still well below the US Medical Equipment average of 2.9x and the fair ratio of 3.4x that the market could move towards. That mix of small premium to peers and large gap to the fair ratio creates both opportunity and valuation risk, so it is worth considering which side of that trade-off feels more compelling to you.

Next Steps

After all this sentiment around Alphatec Holdings, it makes sense to check the numbers yourself and decide where you stand. To see why some investors are optimistic, take a closer look at the 2 key rewards

Looking For More Investment Ideas Beyond Alphatec Holdings?

If Alphatec Holdings has sharpened your focus, now is the time to widen your watchlist and line up your next potential opportunities using structured stock ideas.

• Target potential mispricings by scanning 51 high quality undervalued stocks that combine quality fundamentals with a gap between price and intrinsic worth.
• Strengthen the defensive side of your portfolio by reviewing 79 resilient stocks with low risk scores that carry more resilient risk scores.
• Get ahead of the crowd by checking the screener containing 19 high quality undiscovered gems before they appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.